

Atticus in the News
Atticus Pharma is a therapeutics company developing drugs for immunodermatology and associated diseases. Our two initial programs are for the treatment of cutaneous lupus lesions and androgenic alopecia. Atticus licensed from Zylö Therapeutics the Z-pod® sustained-release technology that originated at Albert Einstein College of Medicine that was further developed at Zylö. The technology provides a depot-like effect and enables delivery of therapeutic agents (small molecules, peptides, siRNA) in a sustained-release manner. Some of the news items listed below were issued by Zylö prior to the license being forged, but relate to Atticus and its various programs.

Atticus accepted into NYU's Endless Frontier Labs [EFL] Mentorship Program
Only 78 of over 1,400 applicants accepted into this prestigious program that is designed to optimize each startup’s chance of scaling into a successful company.


